TLC-NOSF Dressings as a First-Line Local Treatment of Chronic Wounds: A Systematic Review of Clinical Evidence
Summary: A landmark systematic review published in the Journal of Wound Care (October 2024) provides the most comprehensive synthesis to date of clinical evidence supporting lipidocolloid technology with nano-oligosaccharide factor (TLC-NOSF) dressings — the UrgoStart dressing range (Laboratoires Urgo, France) — as a first-line local treatment for chronic wounds. Although multiple national and international guidelines already recommend TLC-NOSF dressings, they remain widely prescribed as second-line options in practice, leading to delayed patient benefit and increased payer costs. The review, conducted by an 23-member international panel, searched MEDLINE, Embase, Emcare, and Google Scholar through February 2024 with no language or time restrictions. Seventeen studies meeting eligibility criteria were included, encompassing 10,191 patients and 10,203 wounds across diabetic foot ulcers (DFUs), leg ulcers, pressure injuries, and other chronic wound types — 7,775 treated with TLC-NOSF and 2,428 with comparators. TLC-NOSF dressings function through a unique healing matrix: the TLC component forms a lipidocolloid gel on contact with exudate that prevents dressing adherence and trauma, while the NOSF (sucrose octasulfate) fraction inhibits matrix metalloproteinases (MMPs) that drive wound chronicity and has been shown to improve transcutaneous oxygen pressure, indicating microcirculation enhancement. Three comparative categories were analyzed: TLC-NOSF vs. standard dressings (both first-line, nine studies); first-line vs. second-line TLC-NOSF use (eight studies); and first-line use without a control group (five studies). Across all categories, first-line TLC-NOSF use produced healing rates of 70–80% by weeks 20–24, mean time-to-heal of approximately seven weeks, measurable quality of life improvements, strong patient tolerability and acceptance, and cost savings vs. comparators. Real-world evidence mirrored RCT outcomes across settings and patient populations. The review’s conclusions are aligned with NICE guidance (updated 2023) and French Haute Autorité de Santé recognition, and support the argument that withholding TLC-NOSF as a first-line intervention represents a missed clinical and economic opportunity.
Key Highlights:
- 17 studies, 10,191 patients, 10,203 wounds: TLC-NOSF as first-line treatment consistently outperformed standard dressings on healing rate, time-to-heal, QoL, and cost
- Healing rates 70–80% by weeks 20–24; mean time-to-heal ~7 weeks — with slightly longer times for more severe wound prognosis
- Mechanism: TLC matrix prevents dressing trauma and reduces MMP activity; NOSF (sucrose octasulfate) improves microcirculation and tcpO2 in DFUs
- First-line vs. second-line comparison (8 studies): earlier initiation consistently produced superior outcomes — supporting immediate adoption at first patient presentation
- Real-world evidence confirms RCT results across different healthcare settings, patient demographics, and wound types
- NICE guidance (2023) recommends UrgoStart for VLUs and DFUs; estimated NHS savings of £5.4M/year if universally applied — yet second-line use persists, representing an unresolved implementation gap
Keywords: TLC-NOSF dressings, UrgoStart, chronic wound dressings, sucrose octasulfate, matrix metalloproteinase wound, wound healing systematic review
Marco Meloni Hester Colboc David G. Armstrong Joachim Dissemond Gerry Rayman José-Luis Lázaro-Martínez Rodrigo Rial Agnès Hartemann Leanne Atkin Terry Swanson Michele Goodeve Ralf Lobmann Martin Storck Knut Kröger Sebastian Borys Harikrishna KR Nair Sanjay Vaidya Thua Nguyen Tran Bao Le Thai Huynh Laetitia Thomassin Serge Bohbot Chris Manu Sylvie Meaume